GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise

Zacks01-22

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY, rose 3% and 2.3% on Tuesday, respectively, after results from a study ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2505272710?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-22 21:53","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2505272710","market":"us","top_or_hot":-1,"title":"GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise","media":"Zacks","content":"<div>\n<p>The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY, rose 3% and 2.3% on Tuesday, respectively, after results from a study ...</p>\n\n<a href=\"https://finance.yahoo.com/news/glp-1-drugs-cut-risk-135300779.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-22 21:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/glp-1-drugs-cut-risk-135300779.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY, rose 3% and 2.3% on Tuesday, respectively, after results from a study ...</p>\n\n<a href=\"https://finance.yahoo.com/news/glp-1-drugs-cut-risk-135300779.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1069344957.HKD","symbol_name":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","start_time":0,"source_url":"https://finance.yahoo.com/news/glp-1-drugs-cut-risk-135300779.html","article_id":"2505272710","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505272710","pubTimestamp":1737553980,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY, rose 3% and 2.3% on Tuesday, respectively, after results from a study showed that GLP-1 drugs cut the risk of several heart conditions, kidney diseases and brain ailments.New evidence regarding the additional benefits  and risks of glucagon-like peptide-1  receptor agonists from a large study in nearly two million diabetes patients was published in Nature Medicine on Jan. 20, 2025.Data from the study, conducted over roughly 3.5 years, suggest that GLP-1 drugs compared to other diabetes medications were associated with a reduced risk of numerous conditions, including heart disease, stroke and kidney disease. They decreased the risk of psychotic disorders by 18%, Alzheimer’s disease by 12% and addiction disorders by an average of 13%.Novo Nordisk markets its blockbuster semaglutide  medicines as Ozempic pre-filled pens and Rybelsus oral tablets for type II diabet","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2063271972.USD":"富兰克林创新领域基金","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","AMGN":"安进","LU0097036916.USD":"贝莱德美国增长A2 USD","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","BK4139":"生物科技","NVO":"诺和诺德","LLY":"礼来","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","VKTX":"Viking Therapeutics, Inc.","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","GLP":"全球合伙","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU0079474960.USD":"联博美国增长基金A","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC"},"translate_title":"GLP-1药物降低阿尔茨海默氏症风险，NVO和LLY股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":1,"GLP":1,"AMGN":1,"LLY":1,"NVO":1},"content_text":"The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY, rose 3% and 2.3% on Tuesday, respectively, after results from a study showed that GLP-1 drugs cut the risk of several heart conditions, kidney diseases and brain ailments.\nNew evidence regarding the additional benefits (besides weight loss) and risks of glucagon-like peptide-1 (GLP-1) receptor agonists from a large study in nearly two million diabetes patients was published in Nature Medicine on Jan. 20, 2025. \nData from the study, conducted over roughly 3.5 years, suggest that GLP-1 drugs compared to other diabetes medications were associated with a reduced risk of numerous conditions, including heart disease, stroke and kidney disease. They decreased the risk of psychotic disorders by 18%, Alzheimer’s disease by 12% and addiction disorders by an average of 13%.\nNovo Nordisk markets its blockbuster semaglutide (GLP-1) medicines as Ozempic pre-filled pens and Rybelsus oral tablets for type II diabetes (T2D) and Wegovy injections for weight management. NVO’s arch-rival, Lilly, markets tirzepatide, a dual GIP and GLP-1 receptor agonist, as Mounjaro for T2D and Zepbound for obesity.\nIn the past three months, shares of Novo Nordisk and Lilly have plunged 30% and 17.8%, respectively, compared with the industry’s 16.4% decline.\nImage Source: Zacks Investment Research\nThe data from the study corroborates the results from an exploratory one-year study of semaglutide conducted by the University of Oxford, announced in July 2024. Data from the study showed that semaglutide was associated with benefits like lowering the risk of cognitive problems and nicotine misuse. The study found that the drug was not associated with a risk of adverse neuropsychiatric outcomes compared with other antidiabetic medications. \nHowever, the study results published in Nature Medicine suggest that GLP-1 drugs are associated with increasing the risk of developing arthritis and pancreatitis.\nLabel Expansion Efforts for Wegovy and Zepbound\nNovo Nordisk’s Wegovy and Lilly’s Zepbound have both seen strong sales since launch due to tremendous demand in the market for weight-loss drugs. However, supply issues and strict regulations for insurance coverage have resulted in a slowdown in the sales growth of these drugs in recent quarters.\nNVO and LLY have been working on expanding the labels of their respective obesity medicines for several indications like cardiovascular risk reduction, sleep apnea or metabolic dysfunction-associated steatohepatitis (MASH) among others to ensure insurance coverage under Medicare and better patient access.\nWegovy is already approved in the United States and EU to reduce the risks of major adverse cardiovascular events, including cardiovascular death, non-fatal heart attack or stroke in adults with either overweight or obesity and established cardiovascular disease. The company is also looking to expand Wegovy’s indication to patients with heart failure with preserved ejection fraction (HFpEF).\nLast month, the FDA approved a second indication for Lilly’s Zepbound for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. With the approval, Zepbound became the first and only prescription drug approved for treating adults with moderate-to-severe OSA and obesity. Lilly has also filed regulatory applications in the United States and EU to seek approval for tirzepatide for heart failure with HFpEF. A phase III cardiovascular outcome study is also ongoing. A phase II study in MASH met its primary endpoint in 2024.\nApproval for such additional indications will further boost sales of these drugs in the long term.\nCompetition Heating Up in the Obesity Market\nSeveral companies like Amgen AMGN and Viking Therapeutics VKTX are making rapid progress in the development of novel GLP-1-based candidates for obesity in their clinical pipeline.\nIn November 2024, Amgen announced 52-week top-line data from a phase II study on MariTide, its GIPR/GLP-1 receptor for obesity for obesity. The data showed that MariTide led to approximately 20% average weight loss over 52 weeks without reaching a weight loss plateau. Amgen began a phase II study on the candidate for T2D in the third quarter.\nAmgen plans to conduct a broad phase III program on MariTide across obesity, obesity-related conditions and T2D. AMGN and VKTX’s products can pose strong competition to Mounjaro/Zepbound and Ozempic/Wegovy in the future.\nNVO & LLY’s Zacks Ranks\nNovo Nordisk carries a Zacks Rank #4 (Sell), while Eli Lilly has a Zacks Rank #3 (Hold) at present.\nYou can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nNovo Nordisk A/S (NVO) : Free Stock Analysis Report\nEli Lilly and Company (LLY) : Free Stock Analysis Report\nAmgen Inc. (AMGN) : Free Stock Analysis Report\nViking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2505272710"}